GSK-3 inhibitors (Takeda)

N/A

Report date: 2025/02/01 20:00:06

NME

Base Information

Drug NameGSK-3 inhibitors (Takeda)

Drug Alias NameGSK-3 beta inhibitors (Takeda)GSK-3 alpha/beta inhibitors (Takeda)MMBO

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionGlycogen synthase kinase-3 alpha inhibitorsMicrotubule-associated protein tau inhibitorsGlycogen synthase kinase-3 beta inhibitors

TargetsGlycogen synthase kinase-3 alphaGlycogen synthase kinase-3 betaMicrotubule-associated protein tau

Therapy Area/IndicationsAlzheimer Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesTakeda Pharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesTakeda Pharmaceutical Co Ltd

Active IndicationsN/A

Inactive IndicationsAlzheimer Disease

Other Information

ATC CodeN/A